Assertio (NASDAQ:ASRT) Issues Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Key Points

• Assertio reported a quarterly loss of ($0.17) EPS, which was $0.11 below analysts' expectations of ($0.06).
• The company has a negative return on equity of 24.87% and a negative net margin of 25.72%.
• Following the earnings report, Wall Street analysts showed mixed sentiments, with some downgrading the stock and others maintaining a buy rating with a target price of $3.50.

Assertio (NASDAQ:ASRT - Get Free Report) issued its earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.07), Zacks reports. Assertio had a negative net margin of 25.72% and a negative return on equity of 24.87%. The firm had revenue of $29.22 million during the quarter, compared to analyst estimates of $27.86 million. Assertio updated its FY 2025 guidance to EPS.

Assertio Stock Down 0.5%

ASRT stock opened at $0.73 on Tuesday. The company has a current ratio of 1.66, a quick ratio of 1.35 and a debt-to-equity ratio of 0.36. Assertio has a twelve month low of $0.51 and a twelve month high of $1.38. The company's 50 day moving average is $0.68 and its two-hundred day moving average is $0.70. The stock has a market cap of $69.44 million, a P/E ratio of -2.27 and a beta of 0.28.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ASRT shares. HC Wainwright reissued a "buy" rating and set a $3.50 price objective on shares of Assertio in a report on Monday, May 19th. Alliance Global Partners reissued a "buy" rating on shares of Assertio in a report on Tuesday, May 13th. Finally, Wall Street Zen cut shares of Assertio from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.